NL7906761A - Nieuwe 4-anilinochinazoline verbindingen en hun bereiding. - Google Patents
Nieuwe 4-anilinochinazoline verbindingen en hun bereiding. Download PDFInfo
- Publication number
- NL7906761A NL7906761A NL7906761A NL7906761A NL7906761A NL 7906761 A NL7906761 A NL 7906761A NL 7906761 A NL7906761 A NL 7906761A NL 7906761 A NL7906761 A NL 7906761A NL 7906761 A NL7906761 A NL 7906761A
- Authority
- NL
- Netherlands
- Prior art keywords
- group
- atom
- hydrogen atom
- compounds
- quinazoline
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 74
- 238000002360 preparation method Methods 0.000 title claims description 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 24
- -1 aniline compound Chemical class 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 230000000202 analgesic effect Effects 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000730 antalgic agent Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 239000012458 free base Substances 0.000 claims description 7
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- NSCRIMVWSSNPQO-UHFFFAOYSA-N n-methyl-n-phenyl-7-(trifluoromethyl)quinazolin-4-amine Chemical compound N=1C=NC2=CC(C(F)(F)F)=CC=C2C=1N(C)C1=CC=CC=C1 NSCRIMVWSSNPQO-UHFFFAOYSA-N 0.000 claims description 2
- QQCFPFVGDZKUTF-UHFFFAOYSA-N n-phenyl-7-(trifluoromethyl)quinazolin-4-amine Chemical compound N=1C=NC2=CC(C(F)(F)F)=CC=C2C=1NC1=CC=CC=C1 QQCFPFVGDZKUTF-UHFFFAOYSA-N 0.000 claims description 2
- MTSNDBYBIZSILH-UHFFFAOYSA-N n-phenylquinazolin-4-amine Chemical class N=1C=NC2=CC=CC=C2C=1NC1=CC=CC=C1 MTSNDBYBIZSILH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000012442 inert solvent Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- 238000000354 decomposition reaction Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 238000002844 melting Methods 0.000 description 16
- 230000008018 melting Effects 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- 238000000921 elemental analysis Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- FDPHWQSGEWRZOL-UHFFFAOYSA-N 4,7-dichloroquinazoline Chemical compound ClC1=NC=NC2=CC(Cl)=CC=C21 FDPHWQSGEWRZOL-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IJNDITTYYNJLPT-UHFFFAOYSA-N 4-chloro-7-(trifluoromethyl)quinazoline Chemical compound ClC1=NC=NC2=CC(C(F)(F)F)=CC=C21 IJNDITTYYNJLPT-UHFFFAOYSA-N 0.000 description 2
- SLUNGDFHPGKYSO-UHFFFAOYSA-N 7-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine Chemical compound C1=CC(OC)=CC=C1N(C)C1=NC=NC2=CC(Cl)=CC=C12 SLUNGDFHPGKYSO-UHFFFAOYSA-N 0.000 description 2
- AQLFYKIRDFAQFS-UHFFFAOYSA-N 7-chloro-n-(4-methoxyphenyl)quinazolin-4-amine Chemical compound C1=CC(OC)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 AQLFYKIRDFAQFS-UHFFFAOYSA-N 0.000 description 2
- WQTBXXKRJZOWDA-UHFFFAOYSA-N 8-chloro-n-phenylquinazolin-4-amine Chemical compound N1=CN=C2C(Cl)=CC=CC2=C1NC1=CC=CC=C1 WQTBXXKRJZOWDA-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 239000012433 hydrogen halide Substances 0.000 description 2
- 229910000039 hydrogen halide Inorganic materials 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- AHLKSOXEVRYIRD-UHFFFAOYSA-N n-phenylquinazolin-2-amine Chemical class N=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 AHLKSOXEVRYIRD-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- VBUBADWLHFZFDK-UHFFFAOYSA-N quinazoline;hydrochloride Chemical compound Cl.N1=CN=CC2=CC=CC=C21 VBUBADWLHFZFDK-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical compound ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 description 1
- TUQSVSYUEBNNKQ-UHFFFAOYSA-N 2,4-dichloroquinazoline Chemical compound C1=CC=CC2=NC(Cl)=NC(Cl)=C21 TUQSVSYUEBNNKQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NUEXBMWGXUGHJI-UHFFFAOYSA-N 5-chloro-n-phenylquinazolin-4-amine;hydrochloride Chemical compound Cl.C=12C(Cl)=CC=CC2=NC=NC=1NC1=CC=CC=C1 NUEXBMWGXUGHJI-UHFFFAOYSA-N 0.000 description 1
- PELUEZKVCSTJDS-UHFFFAOYSA-N 6-chloro-n-(2-chlorophenyl)quinazolin-4-amine Chemical compound C12=CC(Cl)=CC=C2N=CN=C1NC1=CC=CC=C1Cl PELUEZKVCSTJDS-UHFFFAOYSA-N 0.000 description 1
- OUAXFKDZJLIAFU-UHFFFAOYSA-N 6-chloro-n-(2-chlorophenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C12=CC(Cl)=CC=C2N=CN=C1NC1=CC=CC=C1Cl OUAXFKDZJLIAFU-UHFFFAOYSA-N 0.000 description 1
- FFECIXYXEXOTDZ-UHFFFAOYSA-N 6-chloro-n-(2-methoxyphenyl)quinazolin-4-amine Chemical compound COC1=CC=CC=C1NC1=NC=NC2=CC=C(Cl)C=C12 FFECIXYXEXOTDZ-UHFFFAOYSA-N 0.000 description 1
- PROIXVJVWLVGMH-UHFFFAOYSA-N 6-chloro-n-(2-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC=C1NC1=NC=NC2=CC=C(Cl)C=C12 PROIXVJVWLVGMH-UHFFFAOYSA-N 0.000 description 1
- UJOGZSQDODHMQC-UHFFFAOYSA-N 6-chloro-n-(2-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.CC1=CC=CC=C1NC1=NC=NC2=CC=C(Cl)C=C12 UJOGZSQDODHMQC-UHFFFAOYSA-N 0.000 description 1
- NGXVMQDAJBWKHA-UHFFFAOYSA-N 6-chloro-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC(Cl)=CC=C3N=CN=2)=C1 NGXVMQDAJBWKHA-UHFFFAOYSA-N 0.000 description 1
- ABBPNYOYICXNEL-UHFFFAOYSA-N 6-chloro-n-(3-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.CC1=CC=CC(NC=2C3=CC(Cl)=CC=C3N=CN=2)=C1 ABBPNYOYICXNEL-UHFFFAOYSA-N 0.000 description 1
- WUMKCFASXDJFNA-UHFFFAOYSA-N 6-chloro-n-(4-chlorophenyl)quinazolin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC=NC2=CC=C(Cl)C=C12 WUMKCFASXDJFNA-UHFFFAOYSA-N 0.000 description 1
- KPWJLPDCIKAAKN-UHFFFAOYSA-N 6-chloro-n-(4-chlorophenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1NC1=NC=NC2=CC=C(Cl)C=C12 KPWJLPDCIKAAKN-UHFFFAOYSA-N 0.000 description 1
- SFHBQVMAXMRHGK-UHFFFAOYSA-N 6-chloro-n-(4-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1NC1=NC=NC2=CC=C(Cl)C=C12 SFHBQVMAXMRHGK-UHFFFAOYSA-N 0.000 description 1
- WBXRILDIUUXORU-UHFFFAOYSA-N 7-chloro-N-(4-chlorophenyl)-N-ethylquinazolin-4-amine Chemical compound N=1C=NC2=CC(Cl)=CC=C2C=1N(CC)C1=CC=C(Cl)C=C1 WBXRILDIUUXORU-UHFFFAOYSA-N 0.000 description 1
- SVCUXJXYMGQOQG-UHFFFAOYSA-N 7-chloro-N-(4-chlorophenyl)-N-ethylquinazolin-4-amine hydrochloride Chemical compound Cl.N=1C=NC2=CC(Cl)=CC=C2C=1N(CC)C1=CC=C(Cl)C=C1 SVCUXJXYMGQOQG-UHFFFAOYSA-N 0.000 description 1
- FJNNROGRORVFIT-UHFFFAOYSA-N 7-chloro-N-(4-chlorophenyl)-N-methylquinazolin-4-amine hydrochloride Chemical compound Cl.N=1C=NC2=CC(Cl)=CC=C2C=1N(C)C1=CC=C(Cl)C=C1 FJNNROGRORVFIT-UHFFFAOYSA-N 0.000 description 1
- ZOUVUHTVKMKRIQ-UHFFFAOYSA-N 7-chloro-N-(4-ethoxyphenyl)-N-methylquinazolin-4-amine Chemical compound C1=CC(OCC)=CC=C1N(C)C1=NC=NC2=CC(Cl)=CC=C12 ZOUVUHTVKMKRIQ-UHFFFAOYSA-N 0.000 description 1
- NLRLCSXPZPGZCX-UHFFFAOYSA-N 7-chloro-N-(4-ethoxyphenyl)-N-methylquinazolin-4-amine hydrochloride Chemical compound Cl.C1=CC(OCC)=CC=C1N(C)C1=NC=NC2=CC(Cl)=CC=C12 NLRLCSXPZPGZCX-UHFFFAOYSA-N 0.000 description 1
- RCELMRYNPFGAPL-UHFFFAOYSA-N 7-chloro-N-(4-ethylphenyl)-N-methylquinazolin-4-amine Chemical compound C1=CC(CC)=CC=C1N(C)C1=NC=NC2=CC(Cl)=CC=C12 RCELMRYNPFGAPL-UHFFFAOYSA-N 0.000 description 1
- RQMJVZYXVXMOTJ-UHFFFAOYSA-N 7-chloro-n-(2-chlorophenyl)quinazolin-4-amine Chemical compound N=1C=NC2=CC(Cl)=CC=C2C=1NC1=CC=CC=C1Cl RQMJVZYXVXMOTJ-UHFFFAOYSA-N 0.000 description 1
- DXLUHJFDYKVQFG-UHFFFAOYSA-N 7-chloro-n-(2-chlorophenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(Cl)=CC=C2C=1NC1=CC=CC=C1Cl DXLUHJFDYKVQFG-UHFFFAOYSA-N 0.000 description 1
- LQJLOHNPDBDDQO-UHFFFAOYSA-N 7-chloro-n-(2-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 LQJLOHNPDBDDQO-UHFFFAOYSA-N 0.000 description 1
- TYROGPJZKOKRFE-UHFFFAOYSA-N 7-chloro-n-(2-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.CC1=CC=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 TYROGPJZKOKRFE-UHFFFAOYSA-N 0.000 description 1
- NFUBGMMOTSKOBZ-UHFFFAOYSA-N 7-chloro-n-(3-chlorophenyl)quinazolin-4-amine Chemical compound ClC1=CC=CC(NC=2C3=CC=C(Cl)C=C3N=CN=2)=C1 NFUBGMMOTSKOBZ-UHFFFAOYSA-N 0.000 description 1
- QJKWBKXJXWPIAB-UHFFFAOYSA-N 7-chloro-n-(3-chlorophenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.ClC1=CC=CC(NC=2C3=CC=C(Cl)C=C3N=CN=2)=C1 QJKWBKXJXWPIAB-UHFFFAOYSA-N 0.000 description 1
- CCOFIBUWORQGQX-UHFFFAOYSA-N 7-chloro-n-(3-methylphenyl)quinazolin-4-amine Chemical compound CC1=CC=CC(NC=2C3=CC=C(Cl)C=C3N=CN=2)=C1 CCOFIBUWORQGQX-UHFFFAOYSA-N 0.000 description 1
- IZYNRPNAKZIFQI-UHFFFAOYSA-N 7-chloro-n-(4-chlorophenyl)-n-methylquinazolin-4-amine Chemical compound N=1C=NC2=CC(Cl)=CC=C2C=1N(C)C1=CC=C(Cl)C=C1 IZYNRPNAKZIFQI-UHFFFAOYSA-N 0.000 description 1
- IZBISXIQHKUYQT-UHFFFAOYSA-N 7-chloro-n-(4-chlorophenyl)quinazolin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 IZBISXIQHKUYQT-UHFFFAOYSA-N 0.000 description 1
- ZBCFAEMZFNNRIN-UHFFFAOYSA-N 7-chloro-n-(4-chlorophenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 ZBCFAEMZFNNRIN-UHFFFAOYSA-N 0.000 description 1
- SSRRLGRCEHXVHO-UHFFFAOYSA-N 7-chloro-n-(4-ethoxyphenyl)quinazolin-4-amine Chemical compound C1=CC(OCC)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 SSRRLGRCEHXVHO-UHFFFAOYSA-N 0.000 description 1
- NXNIUPIRPQJQLY-UHFFFAOYSA-N 7-chloro-n-(4-ethoxyphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(OCC)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 NXNIUPIRPQJQLY-UHFFFAOYSA-N 0.000 description 1
- OTSXKMYUSGJPOI-UHFFFAOYSA-N 7-chloro-n-(4-ethylphenyl)quinazolin-4-amine Chemical compound C1=CC(CC)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 OTSXKMYUSGJPOI-UHFFFAOYSA-N 0.000 description 1
- JTGCXUHQLHUCCS-UHFFFAOYSA-N 7-chloro-n-(4-methoxyphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 JTGCXUHQLHUCCS-UHFFFAOYSA-N 0.000 description 1
- DABFAYQAMWWQGS-UHFFFAOYSA-N 7-chloro-n-(4-methylphenyl)quinazolin-4-amine Chemical compound C1=CC(C)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 DABFAYQAMWWQGS-UHFFFAOYSA-N 0.000 description 1
- LWAVUCPYWUUCJQ-UHFFFAOYSA-N 7-chloro-n-(4-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 LWAVUCPYWUUCJQ-UHFFFAOYSA-N 0.000 description 1
- BJGJGGRRNGGXHQ-UHFFFAOYSA-N 7-chloro-n-ethyl-n-phenylquinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(Cl)=CC=C2C=1N(CC)C1=CC=CC=C1 BJGJGGRRNGGXHQ-UHFFFAOYSA-N 0.000 description 1
- YCOYSRJAJIEPKF-UHFFFAOYSA-N 7-chloro-n-methyl-n-(4-methylphenyl)quinazolin-4-amine Chemical compound N=1C=NC2=CC(Cl)=CC=C2C=1N(C)C1=CC=C(C)C=C1 YCOYSRJAJIEPKF-UHFFFAOYSA-N 0.000 description 1
- XXFORLYQKWJLOP-UHFFFAOYSA-N 7-chloro-n-methyl-n-(4-methylphenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(Cl)=CC=C2C=1N(C)C1=CC=C(C)C=C1 XXFORLYQKWJLOP-UHFFFAOYSA-N 0.000 description 1
- BQHCBTCXGZBOKV-UHFFFAOYSA-N 7-chloro-n-methyl-n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC(Cl)=CC=C2C=1N(C)C1=CC=CC=C1 BQHCBTCXGZBOKV-UHFFFAOYSA-N 0.000 description 1
- GZLRRAAMOVHEKU-UHFFFAOYSA-N 7-chloro-n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC(Cl)=CC=C2C=1NC1=CC=CC=C1 GZLRRAAMOVHEKU-UHFFFAOYSA-N 0.000 description 1
- RVANTFFGGVRGMT-UHFFFAOYSA-N 7-chloro-n-phenylquinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(Cl)=CC=C2C=1NC1=CC=CC=C1 RVANTFFGGVRGMT-UHFFFAOYSA-N 0.000 description 1
- UCOCWQKCNYEVMY-UHFFFAOYSA-N 7-fluoro-n-phenylquinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(F)=CC=C2C=1NC1=CC=CC=C1 UCOCWQKCNYEVMY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SEMDVFOVFZWLND-UHFFFAOYSA-N 8-chloro-n-(3-chlorophenyl)quinazolin-4-amine Chemical compound ClC1=CC=CC(NC=2C3=CC=CC(Cl)=C3N=CN=2)=C1 SEMDVFOVFZWLND-UHFFFAOYSA-N 0.000 description 1
- MIDPAEUIXBVECE-UHFFFAOYSA-N 8-chloro-n-(3-chlorophenyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.ClC1=CC=CC(NC=2C3=CC=CC(Cl)=C3N=CN=2)=C1 MIDPAEUIXBVECE-UHFFFAOYSA-N 0.000 description 1
- QYVUIJCFAQESDK-UHFFFAOYSA-N 8-chloro-n-methyl-n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=C(Cl)C=CC=C2C=1N(C)C1=CC=CC=C1 QYVUIJCFAQESDK-UHFFFAOYSA-N 0.000 description 1
- GADYULKNUPBDEV-UHFFFAOYSA-N 8-chloro-n-methyl-n-phenylquinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=C(Cl)C=CC=C2C=1N(C)C1=CC=CC=C1 GADYULKNUPBDEV-UHFFFAOYSA-N 0.000 description 1
- KOAOERVORSOTKI-UHFFFAOYSA-N 8-chloroquinazoline Chemical compound N1=CN=C2C(Cl)=CC=CC2=C1 KOAOERVORSOTKI-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- SYKNUAWMBRIEKB-UHFFFAOYSA-N [Cl].[Br] Chemical group [Cl].[Br] SYKNUAWMBRIEKB-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- JDWKBOKDXKLION-UHFFFAOYSA-N n-(4-bromophenyl)-6-chloroquinazolin-4-amine;hydrochloride Chemical compound Cl.C12=CC(Cl)=CC=C2N=CN=C1NC1=CC=C(Br)C=C1 JDWKBOKDXKLION-UHFFFAOYSA-N 0.000 description 1
- YIRGGUQZBWLPMS-UHFFFAOYSA-N n-(4-butylphenyl)-7-chloroquinazolin-4-amine Chemical compound C1=CC(CCCC)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 YIRGGUQZBWLPMS-UHFFFAOYSA-N 0.000 description 1
- WYPVGUUTYKLDCY-UHFFFAOYSA-N n-(4-butylphenyl)-7-chloroquinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(CCCC)=CC=C1NC1=NC=NC2=CC(Cl)=CC=C12 WYPVGUUTYKLDCY-UHFFFAOYSA-N 0.000 description 1
- SIPFPNIXFDPOKX-UHFFFAOYSA-N n-(4-methoxyphenyl)-7-(trifluoromethyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1NC1=NC=NC2=CC(C(F)(F)F)=CC=C12 SIPFPNIXFDPOKX-UHFFFAOYSA-N 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- GCHXFZLRSXKKTF-UHFFFAOYSA-N n-methyl-7-nitro-n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC([N+]([O-])=O)=CC=C2C=1N(C)C1=CC=CC=C1 GCHXFZLRSXKKTF-UHFFFAOYSA-N 0.000 description 1
- PLBOQRFSJPUONM-UHFFFAOYSA-N n-methyl-7-nitro-n-phenylquinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC([N+]([O-])=O)=CC=C2C=1N(C)C1=CC=CC=C1 PLBOQRFSJPUONM-UHFFFAOYSA-N 0.000 description 1
- BWUNGJFWIWASPC-UHFFFAOYSA-N n-methyl-n-phenyl-7-(trifluoromethyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(C(F)(F)F)=CC=C2C=1N(C)C1=CC=CC=C1 BWUNGJFWIWASPC-UHFFFAOYSA-N 0.000 description 1
- INRKACJERWNBAO-UHFFFAOYSA-N n-methyl-n-phenyl-8-(trifluoromethyl)quinazolin-4-amine Chemical compound N=1C=NC2=C(C(F)(F)F)C=CC=C2C=1N(C)C1=CC=CC=C1 INRKACJERWNBAO-UHFFFAOYSA-N 0.000 description 1
- LEILVIVDWHYMHG-UHFFFAOYSA-N n-methyl-n-phenyl-8-(trifluoromethyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=C(C(F)(F)F)C=CC=C2C=1N(C)C1=CC=CC=C1 LEILVIVDWHYMHG-UHFFFAOYSA-N 0.000 description 1
- VCLXUEIYTZFLMO-UHFFFAOYSA-N n-methyl-n-phenylquinazolin-4-amine Chemical compound N=1C=NC2=CC=CC=C2C=1N(C)C1=CC=CC=C1 VCLXUEIYTZFLMO-UHFFFAOYSA-N 0.000 description 1
- LOMNOLXOCXXSLC-UHFFFAOYSA-N n-phenyl-7-(trifluoromethyl)quinazolin-4-amine;hydrochloride Chemical compound Cl.N=1C=NC2=CC(C(F)(F)F)=CC=C2C=1NC1=CC=CC=C1 LOMNOLXOCXXSLC-UHFFFAOYSA-N 0.000 description 1
- AWBGRWSSTIFMRE-UHFFFAOYSA-N n-phenyl-8-(trifluoromethyl)quinazolin-4-amine Chemical compound N1=CN=C2C(C(F)(F)F)=CC=CC2=C1NC1=CC=CC=C1 AWBGRWSSTIFMRE-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical class C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11148478A JPS5538325A (en) | 1978-09-11 | 1978-09-11 | 4-anilinoquinazoline derivative and its preparation |
| JP11148478 | 1978-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL7906761A true NL7906761A (nl) | 1980-03-13 |
Family
ID=14562420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL7906761A NL7906761A (nl) | 1978-09-11 | 1979-09-11 | Nieuwe 4-anilinochinazoline verbindingen en hun bereiding. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US4322420A (pt) |
| JP (1) | JPS5538325A (pt) |
| BE (1) | BE878723A (pt) |
| CA (1) | CA1151168A (pt) |
| CH (1) | CH642361A5 (pt) |
| DE (1) | DE2936705A1 (pt) |
| DK (1) | DK377079A (pt) |
| ES (1) | ES484097A0 (pt) |
| FR (1) | FR2435248A1 (pt) |
| GB (1) | GB2033894B (pt) |
| IT (1) | IT1119933B (pt) |
| NL (1) | NL7906761A (pt) |
| SE (1) | SE446337B (pt) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| JPS57144266A (en) * | 1981-03-04 | 1982-09-06 | Sankyo Co Ltd | 4-anilinoquinazoline derivative, its preparation, and analgesic and antiphlogistic agent containing said derivative as active component |
| JP2676082B2 (ja) * | 1987-12-25 | 1997-11-12 | 住友化学工業株式会社 | ゴキブリ防除用マイクロカプセル剤 |
| WO1992020642A1 (en) * | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| USRE37650E1 (en) | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US6645969B1 (en) * | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5733561A (en) * | 1991-06-12 | 1998-03-31 | Mitsui Toatsu Chemicals, Incorporated | Insecticide composition and production process thereof |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US5234936A (en) * | 1991-10-24 | 1993-08-10 | American Home Products Corporation | Pyrimidocycloalkanes as a ii antagonists |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| ES2049659B1 (es) * | 1992-10-08 | 1994-10-16 | Ici Plc | Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena. |
| GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| AU739382B2 (en) * | 1993-12-10 | 2001-10-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US6232465B1 (en) | 1994-09-02 | 2001-05-15 | Andrew C. Hiatt | Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides |
| US6214987B1 (en) | 1994-09-02 | 2001-04-10 | Andrew C. Hiatt | Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides |
| TW321649B (pt) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| EP0824525B1 (en) * | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
| GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| KR19990082463A (ko) * | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| CN1116286C (zh) * | 1996-03-05 | 2003-07-30 | 曾尼卡有限公司 | 4－苯胺基喹唑啉衍生物 |
| GB9607729D0 (en) * | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US5939421A (en) * | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
| US6706721B1 (en) * | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| MXPA00011773A (es) | 1998-05-28 | 2002-06-04 | Parker Hughes Inst | Quinazolinas para tratar tumores en el cerebro. |
| US6800649B1 (en) | 1998-06-30 | 2004-10-05 | Parker Hughes Institute | Method for inhibiting c-jun expression using JAK-3 inhibitors |
| MXPA01001893A (es) | 1998-08-21 | 2002-04-24 | Parker Hughes Inst | Derivados de quinazolina. |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| US6258820B1 (en) | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
| PT1244647E (pt) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| US7087613B2 (en) * | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| EP1274692B1 (en) | 2000-04-07 | 2006-08-02 | AstraZeneca AB | Quinazoline compounds |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| DE60234057D1 (de) | 2001-07-25 | 2009-11-26 | Raptor Pharmaceutical Inc | Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke |
| MXPA04004219A (es) * | 2001-11-03 | 2004-09-10 | Astrazeneca Ab | Derivados de quinazolina como agentes antitumorales. |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| CN1984660B (zh) * | 2003-07-03 | 2010-12-15 | 美瑞德生物工程公司 | 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉 |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| CN1882573A (zh) * | 2003-09-16 | 2006-12-20 | 阿斯利康(瑞典)有限公司 | 作为酪氨酸激酶抑制剂的喹唑啉衍生物 |
| DK1667992T3 (da) * | 2003-09-19 | 2007-04-30 | Astrazeneca Ab | Quinazolinderivater |
| WO2005028470A1 (en) * | 2003-09-19 | 2005-03-31 | Astrazeneca Ab | Quinazoline derivatives |
| BRPI0414735A (pt) * | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina |
| AU2004285052A1 (en) * | 2003-10-31 | 2005-05-12 | Neurogen Corporation | 4-amino (AZA) quinoline derivatives as capsaicin receptor agonists |
| GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| CN1993349A (zh) * | 2004-06-04 | 2007-07-04 | 阿斯利康(瑞典)有限公司 | 作为erbb受体酪氨酸激酶的喹唑啉衍生物 |
| US20070244114A1 (en) * | 2004-07-06 | 2007-10-18 | Myriad Genetics, Incorporated | Compounds and therapeutical use thereof |
| ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| US8258145B2 (en) * | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| US8735410B2 (en) * | 2005-02-26 | 2014-05-27 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CN103259027A (zh) | 2005-04-28 | 2013-08-21 | 普罗透斯数字保健公司 | 药物信息系统 |
| GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| EP1928861B1 (en) * | 2005-09-20 | 2010-11-17 | AstraZeneca AB | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| JP2009508917A (ja) * | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 抗癌剤としてのキナゾリン誘導体 |
| WO2007063291A1 (en) * | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
| US20090029968A1 (en) * | 2005-12-02 | 2009-01-29 | Bernard Christophe Barlaam | Quinazoline derivatives used as inhibitors of erbb tyrosine kinase |
| US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
| WO2008009078A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| US8246966B2 (en) * | 2006-08-07 | 2012-08-21 | University Of Georgia Research Foundation, Inc. | Trypanosome microsome system and uses thereof |
| KR20090071598A (ko) | 2006-09-18 | 2009-07-01 | 랩터 파마슈티컬 인코포레이티드 | 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료 |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| EP2088863A2 (en) * | 2006-11-22 | 2009-08-19 | University Of Georgia Research Foundation, Inc. | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
| MX2009007610A (es) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. |
| WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
| JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
| PT2398500T (pt) | 2009-02-20 | 2019-06-14 | 2 Bbb Medicines B V | Sistema de entrega de medicamentos à base de glutationas |
| TWI556839B (zh) | 2009-05-06 | 2016-11-11 | 研究室護膚股份有限公司 | 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法 |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| CN110372666B (zh) * | 2018-04-13 | 2022-11-08 | 华东理工大学 | 喹唑啉类化合物作为egfr三突变抑制剂及其应用 |
| BR112021018295A2 (pt) | 2019-03-15 | 2021-11-23 | Univ California | Composições e métodos para tratamento de câncer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1724086A (en) * | 1929-08-13 | Eentrich astd max hardtmankt | ||
| US2794018A (en) * | 1953-08-07 | 1957-05-28 | New quinazoline derivatives | |
| CH492395A (de) * | 1966-04-26 | 1970-06-30 | Sandoz Ag | Mittel zur Bekämpfung von Pflanzenschädlingen und Verwendung des Mittels |
| US3560619A (en) * | 1967-01-03 | 1971-02-02 | Mead Johnson & Co | Aminoquinazolines and quinazolones in treatment of coccidiosis |
| US3702849A (en) * | 1967-10-26 | 1972-11-14 | Pfizer | 4-(isoquinolin-1-yl) piperazine-1-carboxylic acid esters |
| US4041030A (en) * | 1973-09-20 | 1977-08-09 | Delalande S.A. | Arylamino pyrimidinic derivatives |
| US3985749A (en) * | 1975-12-22 | 1976-10-12 | Eastman Kodak Company | Process for preparation of 4-aminoquinazoline |
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
-
1978
- 1978-09-11 JP JP11148478A patent/JPS5538325A/ja active Granted
-
1979
- 1979-09-10 CA CA000335246A patent/CA1151168A/en not_active Expired
- 1979-09-10 SE SE7907493A patent/SE446337B/sv unknown
- 1979-09-10 CH CH816679A patent/CH642361A5/de not_active IP Right Cessation
- 1979-09-10 DK DK377079A patent/DK377079A/da unknown
- 1979-09-10 IT IT68794/79A patent/IT1119933B/it active
- 1979-09-11 FR FR7922639A patent/FR2435248A1/fr active Granted
- 1979-09-11 GB GB7931441A patent/GB2033894B/en not_active Expired
- 1979-09-11 BE BE0/197102A patent/BE878723A/fr not_active IP Right Cessation
- 1979-09-11 DE DE19792936705 patent/DE2936705A1/de not_active Withdrawn
- 1979-09-11 ES ES484097A patent/ES484097A0/es active Granted
- 1979-09-11 NL NL7906761A patent/NL7906761A/nl not_active Application Discontinuation
- 1979-09-11 US US06/074,343 patent/US4322420A/en not_active Expired - Lifetime
-
1981
- 1981-08-03 US US06/289,379 patent/US4464375A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SE7907493L (sv) | 1980-03-12 |
| CH642361A5 (de) | 1984-04-13 |
| GB2033894B (en) | 1983-02-16 |
| JPS626546B2 (pt) | 1987-02-12 |
| IT7968794A0 (it) | 1979-09-10 |
| US4464375A (en) | 1984-08-07 |
| US4322420A (en) | 1982-03-30 |
| GB2033894A (en) | 1980-05-29 |
| CA1151168A (en) | 1983-08-02 |
| FR2435248A1 (fr) | 1980-04-04 |
| ES8100276A1 (es) | 1980-11-01 |
| FR2435248B1 (pt) | 1983-02-18 |
| SE446337B (sv) | 1986-09-01 |
| BE878723A (fr) | 1980-03-11 |
| IT1119933B (it) | 1986-03-19 |
| ES484097A0 (es) | 1980-11-01 |
| DE2936705A1 (de) | 1980-03-20 |
| JPS5538325A (en) | 1980-03-17 |
| DK377079A (da) | 1980-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL7906761A (nl) | Nieuwe 4-anilinochinazoline verbindingen en hun bereiding. | |
| EP0067630B1 (en) | Pyrimidine derivatives, a process for preparing them and a pharmaceutical composition containing them | |
| IE912279A1 (en) | 1-indolylalkyl-4-(alkoxypyrimidinyl)piperazines | |
| US3178348A (en) | Hypotensive quinolines | |
| KR860001252B1 (ko) | 9-[3-(3, 5-시스-디메틸피페라지노)프로필] 카르바졸의 제조방법 | |
| FR2645153A1 (fr) | Derives de la thieno-triazolo-diazepine ainsi que leur procede de preparation | |
| DD249010A5 (de) | Verfahren zur herstellung eines chinolons | |
| NZ207581A (en) | (1h-tetrazol-5-yl)-2(1h)-quinolinone and(1h-tetrazol-5-yl)2(1h)-naphthyridinone derivatives and method for their preparation | |
| Davis et al. | Synthesis of substituted 2, 1-benzisothiazoles | |
| AT394558B (de) | Verfahren zur herstellung neuer 6-phenaethylaminoalkyl-7-hydroxy-furo-(3,4-c)pyridinderivate | |
| DE1695161A1 (de) | Verfahren zur Herstellung von Benzodiazepin-Derivaten | |
| FR2537581A1 (fr) | Derives de triazine utiles comme agents analgesiques, anti-pyretiques et anti-inflammatoires | |
| Wagner | CONDENSATIONS OF AROMATIC AMINES WITH FORMALDEHYDE IN MEDIA CONTAINING ACID. VI. THE USE OF FORMIC ACID IN THE PREPARATION OF 3, 6-DISUBSTITUTED DIHYDROQUINAZOLINES FROM PARA-SUBSTITUTED AMINES, AND FROM THEIR BIS (ARYLAMINO)-METHANES AND SCHIFF BASES | |
| DE1131682B (de) | Verfahren zur Herstellung von N-{[Thiaxanthenyl-(10)]-alkyl}-N'-(hydroxyalkyl)-piperazinen | |
| KR830001347B1 (ko) | 4-아닐리노퀴나졸린 유도체의 제조방법 | |
| DD150604A5 (de) | Verfahren zur herstellung von 9-amino-6,7-dihydro-4h-pyrido(1,2-a)pyrimidin-4-on-derivaten | |
| DD201594A5 (de) | Verfahren zur herstellung von neuen polyazaheterocyclischen verbindungen | |
| BE1003697A3 (fr) | Procede de preparation des nouveaux derives de la thieno-triazolo-diazepine. | |
| Smissman et al. | Intramolecular isomerizations of 5-phenyl-5-(3-aminopropyl) barbituric acids | |
| FR2621314A1 (fr) | Nouveaux derives de quinoleinium et d'isoquinoleinium, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| DK151885B (da) | Fremgangsmaade til fremstilling af pyridooe1,2aaapyrimidin-3-carboxamider eller optisk aktive isomere eller farmaceutisk acceptable salte deraf | |
| JPH04270293A (ja) | 新規オルガノシラン誘導体、それらを含む医薬組成物およびそれらの調製方法 | |
| DE3131064A1 (de) | Benzazepin-derivate | |
| Goldhamer et al. | Analgetic Activity of Some δ-Amino Ketones And Their Derivatives | |
| Whitehead | Some 4-substituted derivatives of 1, 10-phenanthroline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |